Observational studyBMC nephrology2025
Trimethoprim-sulfamethoxazole and the risk of early severe infection in elderly-onset myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has improved survival outcomes with advancements in immunosuppressive therapies; however, the increased incidence of infections remains a significant concern. Reports on infection risk factors other than age are limited, especially in older adults with AAV who are at a higher risk.
methodsWe aimed to identify the risk factors for early-phase infection during treatment initiation in older adults (aged ≥ 75 years) with myeloperoxidase (MPO)-ANCA-positive AAV (MPO-AAV). This was a single-center, retrospective observational study that included 50 patients who were classified as having microscopic polyangiitis. Severe infections were defined as those requiring hospitalization within six months of treatment initiation.
resultsSevere infections occurred in 17 (34%) patients. No statistically significant associations were observed between disease incidence and either combined immunosuppressive therapy or organ-specific lesions. However, trimethoprim-sulfamethoxazole (TMP-SMX) was significantly associated with a reduced risk of infection. This association remained statistically significant after adjustment for sex (hazard ratio, 0.23; 95% CI, 0.08–0.64; P < 0.01).
conclusionsIn older adults with MPO-AAV, TMP-SMX use was associated with a reduced risk of early severe infection. Although limited by the observational nature of the study, these findings suggest a potential role for TMP-SMX prophylaxis in high-risk elderly populations. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.